Phospho-EZR (Y146) Antibody

What is the biological significance of ezrin phosphorylation at Y146?

Ezrin phosphorylation at Y146 plays a critical role in regulating the transition from dormant to active form of ezrin. Unlike the well-characterized phosphorylation site at Thr-567, which is regulated through p38 MAP-kinase pathways, Y146 phosphorylation occurs in the N-ERMAD terminus (F2 subdomain) of ezrin . Research indicates that Y146 phosphorylation contributes to ezrin's membrane localization and its ability to connect the plasma membrane to the actin cytoskeleton . In cancer research contexts, PALM2-dependent phosphorylation of ezrin at Y146 enhances the migration of esophageal squamous cell carcinoma cells, highlighting its importance in cancer progression and metastatic potential .

How does phosphorylation at Y146 differ functionally from other ezrin phosphorylation sites?

Ezrin contains multiple phosphorylation sites that serve distinct functions:

Which experimental models are most suitable for studying ezrin Y146 phosphorylation?

Based on published research, several experimental models have proven effective:

• Cell lines: 293 cells have been successfully used for validating phospho-ezrin (Y146) antibodies . Esophageal squamous cell carcinoma lines (KYSE150, KYSE450, KYSE510) are particularly valuable for investigating Y146 phosphorylation in cancer contexts .

• Animal models: Human, mouse, and rat samples all show reactivity with phospho-ezrin (Y146) antibodies , making these species suitable for in vivo studies.

• Stimulation protocols: UV treatment (15 minutes) of 293 cells has been documented to induce detectable changes in ezrin Y146 phosphorylation, providing a controlled system for studying phosphorylation dynamics .

For investigating cancer-related functions, esophageal squamous cell carcinoma models are particularly informative as they demonstrate the functional relationship between PALM2 prenylation, ezrin Y146 phosphorylation, and cell migration .

What are the optimal conditions for detecting phospho-ezrin (Y146) by Western blot?

For optimal Western blot detection of phospho-ezrin (Y146), follow these evidence-based guidelines:

• Sample preparation:

  • Use cell lysates prepared in buffers containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium pyrophosphate, β-glycerolphosphate)

  • For enhanced detection, treat cells with UV for 15 minutes prior to lysate preparation

• Antibody dilutions:

  • Primary antibody: Use at 1:500-1:2000 dilution

  • Secondary antibody: Follow manufacturer's recommendations for anti-rabbit IgG detection systems

• Controls:

  • Positive control: Lysates from 293 cells treated with UV for 15 minutes

  • Negative control: Include a phospho-peptide blocking control to demonstrate specificity

• Detection protocol:

  • Follow standard Western blot procedures, using PVDF or nitrocellulose membranes

  • Expected molecular weight of ezrin: 69-80 kDa (observed at 69 kDa in most studies)

The validation images from vendor data sheets demonstrate clear detection of phospho-ezrin (Y146) in 293 cells, with significant enhancement of signal after UV treatment .

How can I design experiments to study the functional consequences of ezrin Y146 phosphorylation?

To effectively investigate the functional significance of ezrin Y146 phosphorylation:

• Genetic approaches:

  • Generate phospho-mimetic mutants (Y146D or Y146E) to simulate constitutive phosphorylation

  • Create phospho-deficient mutants (Y146F) to prevent phosphorylation

  • Utilize CRISPR/Cas9 to introduce these mutations at the endogenous locus

• Molecular interaction studies:

  • Investigate binding partners using co-immunoprecipitation with phospho-specific antibodies

  • Examine whether Y146 phosphorylation affects interaction with the PALM2 protein, as suggested by recent research

  • Analyze interactions with FERM domain binding partners

• Cellular phenotype assays:

  • Migration assays (wound healing, transwell) to assess effects on cell motility

  • Subcellular localization studies using immunofluorescence to track membrane association

  • Cell adhesion assays to evaluate attachment dynamics, particularly relevant given evidence that phosphorylated ezrin can inhibit cell adhesion

• Kinase identification:

  • Use kinase inhibitors to identify the specific kinases responsible for Y146 phosphorylation

  • Evidence suggests Src family kinases may regulate Y146 phosphorylation

• Signaling pathway analysis:

  • Investigate connections to PKC signaling pathways, which have been implicated in ezrin phosphorylation and trophoblast cell invasiveness

When designing these experiments, it's important to consider the interplay between different phosphorylation sites, as research suggests possible antagonistic relationships between phosphorylation and acetylation on cell signaling proteins .

What are the best methods for distinguishing between different phosphorylated forms of ezrin in research samples?

Distinguishing between different phosphorylated forms of ezrin requires careful methodological approaches:

• Phospho-specific antibodies:

  • Use validated antibodies specific to each phosphorylation site (Y146, T567, Y353)

  • Confirm specificity with phospho-peptide blocking controls

  • Validate antibody performance with known positive controls (e.g., UV-treated 293 cells for Y146)

• Mass spectrometry approaches:

  • Utilize phospho-enrichment techniques prior to MS analysis

  • Consider sequential immunoprecipitation with phospho-specific antibodies

  • Implement procedures as described in literature: "peptides were purified on a Waters Sep-Pak column, and quantified using a micro-BCA assay... sequentially immunoprecipitated with cocktails of modification-specific antibodies"

• 2D gel electrophoresis:

  • Separate proteins based on both isoelectric point and molecular weight

  • Different phosphorylated forms will migrate differently based on charge modifications

• Phos-tag SDS-PAGE:

  • Use manganese-phos-tag acrylamide gels that specifically retard the migration of phosphorylated proteins

  • This allows visualization of multiple phosphorylated species of the same protein

• Multiplexed detection systems:

  • Implement multi-color immunofluorescence using phospho-specific antibodies with distinct fluorophores

  • Apply TMT (Tandem Mass Tag) labeling for quantitative comparison across samples

The research literature indicates successful use of these approaches, particularly phospho-specific antibodies and mass spectrometry, to distinguish and quantify different ezrin phosphorylation states .

How does PALM2 interaction regulate ezrin Y146 phosphorylation in cancer progression?

Recent research has revealed a complex relationship between prenylated PALM2 and ezrin Y146 phosphorylation in cancer:

• Molecular mechanism:

  • PALM2 directly interacts with the N-terminal FERM domain of ezrin

  • This interaction depends on PALM2 prenylation by farnesyltransferase (FTase)

  • Key residues for interaction include lysines K253/K254/K262/K263 in ezrin's FERM domain and C408 in PALM2's CAAX motif

• Functional consequences:

  • PALM2-dependent ezrin Y146 phosphorylation increases ezrin membrane localization

  • This promotes cancer cell migration in esophageal squamous cell carcinoma

  • Knockout of ezrin prevents enhanced cancer cell migration induced by PALM2 overexpression

• Clinical significance:

  • Upregulated PALM2 is associated with shorter survival time in esophageal cancer patients

  • PALM2 acts as an independent prognostic factor for these patients

• Experimental evidence:

  • PALM2 C408S mutation (preventing prenylation) impairs membranous localization of both PALM2 and ezrin

  • This mutation also eliminates PALM2's ability to enhance cancer cell migration

  • Molecular analysis shows that "prenylated PALM2 enhances the migration of cancer cells by activating ezrin"

This pathway represents a potential therapeutic target, as disrupting PALM2 prenylation or its interaction with ezrin could inhibit cancer cell migration and potentially metastasis.

What is the relationship between ezrin Y146 phosphorylation and other post-translational modifications?

Research has uncovered complex interrelationships between different post-translational modifications (PTMs) of ezrin:

• Phosphorylation crosstalk:

  • Evidence suggests different phosphorylation sites may work cooperatively or antagonistically

  • While T567 phosphorylation is well-established in activating ezrin by disrupting head-to-tail interactions, Y146 phosphorylation appears to regulate membrane localization and protein interactions

  • Research in lung cancer shows that both T567 and Y353 phosphorylation correlate with poor differentiation and late clinical stage, but only T567 phosphorylation correlates with lymph node metastasis

• Phosphorylation-acetylation antagonism:

  • Research indicates "an antagonistic relationship between particular sites of acetylation and phosphorylation on cell signaling proteins"

  • This suggests potential regulatory mechanisms where one modification may inhibit another

• Integration with methylation:

  • Protein methylation changes observed in response to treatments affecting ezrin phosphorylation suggest coordinated regulation

  • This points to a complex regulatory network involving multiple PTM types

• Temporal dynamics:

  • Evidence suggests ezrin undergoes "constitutive both phosphorylation and dephosphorylation in cultured adherent and non-adherent cells"

  • This indicates dynamic regulation rather than static modification states

• Subcellular localization effects:

  • Different PTMs appear to direct ezrin to specific subcellular locations

  • Phosphorylation at Y146 specifically enhances membrane localization

Understanding these complex PTM interrelationships is crucial for developing targeted interventions in disease contexts where ezrin function is dysregulated.

How can phospho-ezrin (Y146) be utilized as a biomarker in cancer research and potential clinical applications?

Emerging research suggests phospho-ezrin (Y146) has potential as a cancer biomarker:

• Cancer type specificity:

  • Current evidence shows particular relevance in esophageal squamous cell carcinoma, where PALM2-dependent Y146 phosphorylation promotes migration

  • Studies in lung cancer have focused more on T567 and Y353 phosphorylation, suggesting different ezrin phosphorylation sites may have cancer-type specific relevance

• Methodological approaches for biomarker development:

  • Immunohistochemistry using phospho-specific antibodies can detect phospho-ezrin in patient tissue samples

  • Western blot analysis of surgical specimens can quantify phosphorylation levels

  • Development of phospho-ezrin ELISA assays could enable higher throughput clinical screening

• Correlations with clinical parameters:

  • Research should investigate whether Y146 phosphorylation, like T567 phosphorylation, correlates with:

    • Tumor stage and differentiation

    • Presence of metastasis

    • Patient survival

• Combination biomarker approach:

  • Analyzing multiple ezrin phosphorylation sites (Y146, T567, Y353) simultaneously may provide more comprehensive prognostic information

  • The PALM2-ezrin axis presents an opportunity for multi-marker analysis

• Therapeutic implications:

  • Elevated phospho-ezrin (Y146) could identify patients who might benefit from targeted therapies

  • Inhibitors targeting the kinases responsible for Y146 phosphorylation could have therapeutic potential

While phospho-ezrin (Y146) shows promise as a biomarker, comprehensive clinical validation studies are still needed to establish its utility across different cancer types and clinical scenarios.

What are common challenges in detecting phospho-ezrin (Y146) and how can they be overcome?

Researchers frequently encounter several challenges when detecting phospho-ezrin (Y146):

• Low signal intensity:

  • Challenge: Baseline phosphorylation levels may be too low for detection

  • Solution: Stimulate cells with treatments known to enhance Y146 phosphorylation (e.g., UV treatment for 15 minutes) ; use more sensitive detection methods like chemiluminescence or fluorescence-based Western blotting

• Specificity concerns:

  • Challenge: Cross-reactivity with other phosphorylated proteins

  • Solution: Include phospho-peptide blocking controls ; validate results using phospho-deficient mutants (Y146F); use multiple antibody clones to confirm findings

• Rapid dephosphorylation:

  • Challenge: Phosphorylation may be lost during sample preparation

  • Solution: Include comprehensive phosphatase inhibitors (sodium orthovanadate, sodium pyrophosphate, β-glycerolphosphate) ; process samples rapidly at cold temperatures

• Antibody batch variability:

  • Challenge: Performance differences between antibody lots

  • Solution: Validate each new lot against known positive controls (UV-treated 293 cells) ; maintain consistent positive controls across experiments

• Background signal:

  • Challenge: High background obscuring specific signal

  • Solution: Optimize blocking conditions; try different blocking agents (BSA vs. milk); increase washing steps; optimize antibody dilution (1:500-1:2000)

• Sample preparation issues:

  • Challenge: Inefficient protein extraction or denaturation

  • Solution: Use optimized lysis buffers containing 1% Triton X-100 and phosphatase inhibitors ; ensure complete denaturation of samples before SDS-PAGE

Following validated protocols and including appropriate controls significantly improves the reliability of phospho-ezrin (Y146) detection.

How should contradictory results from different phospho-ezrin (Y146) antibodies be interpreted and resolved?

When faced with contradictory results from different phospho-ezrin (Y146) antibodies:

• Validation of antibody specificity:

  • Perform phospho-peptide competition assays with each antibody

  • Test antibodies on samples from ezrin knockout cells or cells expressing phospho-deficient mutants (Y146F)

  • Compare reactivity patterns with known positive controls (UV-treated 293 cells)

• Technical considerations:

  • Evaluate whether antibodies recognize different epitopes surrounding Y146

  • Compare antibody formats (polyclonal vs. monoclonal) and species origin

  • Assess optimization requirements for each antibody (dilution, incubation time, temperature)

• Complementary approaches:

  • Implement orthogonal techniques like mass spectrometry to directly measure phosphorylation

  • Use alternative phospho-detection methods like Phos-tag gels

  • Consider in vitro kinase assays to directly establish phosphorylation

• Contextual factors:

  • Determine if contradictions are cell-type or treatment specific

  • Evaluate whether different cell lysis methods affect epitope accessibility

  • Consider the impact of competing PTMs that might mask the Y146 phosphorylation site

• Resolution strategy:

  • Report results with multiple antibodies, clearly indicating their sources

  • Prioritize antibodies with the most extensive validation data

  • Conduct detailed methodological comparisons to identify sources of variability

When reporting contradictory findings, document all methodological details to enable proper interpretation and replication by other researchers.

What are the key considerations when designing experiments to study the relationship between PALM2 and ezrin Y146 phosphorylation?

When investigating the PALM2-ezrin relationship, several critical experimental design considerations should be addressed:

• Protein expression systems:

  • Use tagged constructs (FLAG, HA, Myc, GFP) that don't interfere with PALM2 prenylation or ezrin function

  • Include both wild-type and mutant controls (PALM2 C408S to prevent prenylation; ezrin Y146F to prevent phosphorylation)

  • Consider inducible expression systems to control timing and level of expression

• Subcellular localization analysis:

  • Implement fractionation protocols to separate membrane, cytoplasmic, and nuclear components

  • Use nucleus/cytoplasm fractionation methods as described: "cells were lysed using nuclei extraction buffer (NEB) (0.01 M Tris-HCl pH 8.0, 0.01 M NaCl, 0.003 M MgCl₂, 0.03 M sucrose, 0.5% NP-40) with 1× protease inhibitor cocktail"

  • Complement biochemical fractionation with immunofluorescence microscopy

• Interaction studies:

  • Design co-immunoprecipitation experiments to capture the PALM2-ezrin complex

  • Consider membrane crosslinking approaches to stabilize interactions

  • Map the interaction domains through deletion and point mutations focusing on key residues (K253/K254/K262/K263 in ezrin; C408 in PALM2)

• Functional assays:

  • Implement migration assays (transwell, wound healing) to assess functional consequences

  • Include appropriate controls (ezrin knockout, PALM2 knockout) to establish specificity

  • Measure membrane characteristics (rigidity, tension) which may be affected by ezrin activation

• Phosphorylation analysis:

  • Use phospho-specific antibodies under standardized conditions

  • Implement mass spectrometry approaches for unbiased phosphorylation site identification

  • Consider temporal dynamics through time-course experiments

• Pathway integration:

  • Explore the involvement of farnesyltransferase (FTase) in PALM2 prenylation

  • Investigate kinases potentially responsible for Y146 phosphorylation downstream of PALM2

  • Explore the relationship with other ezrin phosphorylation sites (T567, Y353)

By addressing these considerations, researchers can generate robust data on the PALM2-ezrin signaling axis and its role in cancer cell migration.

What emerging technologies could enhance the study of ezrin Y146 phosphorylation dynamics?

Several cutting-edge technologies show promise for advancing our understanding of ezrin Y146 phosphorylation:

• Live-cell phosphorylation sensors:

  • FRET-based biosensors designed to detect Y146 phosphorylation in real-time

  • Genetically encoded sensors incorporating phospho-binding domains that change conformation upon Y146 phosphorylation

  • These approaches would enable visualization of phosphorylation dynamics with subcellular resolution

• Proximity labeling proteomics:

  • BioID or APEX2 fusions to ezrin to identify proteins proximal to ezrin under different phosphorylation states

  • TurboID-based approaches for faster labeling kinetics to capture dynamic interactions

  • These methods would help identify context-specific binding partners of phospho-ezrin (Y146)

• Single-cell phosphoproteomics:

  • Adaptation of mass cytometry (CyTOF) with phospho-specific antibodies

  • Single-cell Western blot technologies for heterogeneity analysis

  • These approaches would reveal cell-to-cell variability in ezrin phosphorylation within populations

• Cryo-electron microscopy:

  • Structural studies of ezrin conformational changes induced by Y146 phosphorylation

  • Visualization of ezrin-membrane-cytoskeleton interfaces

  • These studies would provide molecular-level insights into how Y146 phosphorylation affects ezrin function

• Phosphoproteomic network analysis:

  • KiNetscape-style visualizations of phosphorylation networks involving ezrin

  • Integration of multiple PTM datasets (phosphorylation, acetylation, methylation) to reveal coordinated regulation

  • These approaches would place ezrin Y146 phosphorylation in broader signaling contexts

• CRISPR-based screening:

  • Focused CRISPR screens targeting kinases and phosphatases to identify regulators of Y146 phosphorylation

  • Base editing approaches to introduce phosphomimetic or phosphodeficient mutations at endogenous loci

  • These technologies would enable systematic discovery of Y146 phosphorylation regulators

Implementation of these technologies would significantly enhance our understanding of ezrin Y146 phosphorylation in normal physiology and disease contexts.

How might the understanding of ezrin Y146 phosphorylation contribute to therapeutic development?

Emerging insights into ezrin Y146 phosphorylation suggest several promising therapeutic strategies:

• Small molecule inhibitors:

  • Target the kinases responsible for Y146 phosphorylation

  • Develop compounds that disrupt the PALM2-ezrin interaction, particularly targeting the critical lysine residues (K253/K254/K262/K263) in ezrin's FERM domain

  • Explore farnesyltransferase inhibitors to prevent PALM2 prenylation, which is required for PALM2-dependent ezrin activation

• Peptide-based therapeutics:

  • Design cell-penetrating peptides that mimic the ezrin FERM domain to competitively inhibit PALM2 binding

  • Develop stabilized peptides that prevent conformational changes associated with Y146 phosphorylation

• Combination therapy approaches:

  • Integrate ezrin phosphorylation inhibitors with existing cancer therapies

  • Target multiple ezrin phosphorylation sites simultaneously (Y146, T567) for enhanced efficacy

  • Combine with cytoskeletal-targeting agents for synergistic effects on cell migration

• Biomarker-guided treatment selection:

  • Use phospho-ezrin (Y146) levels to stratify patients for specific targeted therapies

  • Develop companion diagnostics to monitor treatment efficacy based on ezrin phosphorylation status

• Delivery systems for enhanced specificity:

  • Implement nanoparticle-based delivery of ezrin-targeting therapeutics

  • Explore cancer-specific targeting strategies to minimize effects on normal cells

• Rational drug design opportunities:

  • Utilize structural information about the ezrin Y146 region to design highly specific inhibitors

  • Implement in silico screening approaches to identify compounds that specifically bind the Y146 region